Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA".